IW 6118

Drug Profile

IW 6118

Alternative Names: IW-6118

Latest Information Update: 17 Aug 2015

Price : $50

At a glance

  • Originator Ironwood Pharmaceuticals
  • Class Analgesics; Anti-inflammatories; Small molecules
  • Mechanism of Action Fatty acid amide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammation; Pain

Most Recent Events

  • 31 Dec 2009 Phase-I clinical trials in Pain in USA (PO)
  • 31 Dec 2009 Phase-I clinical trials in Inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top